Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society

In 2022, the European Atherosclerosis Society (EAS) published a new consensus statement on lipoprotein(a) [Lp(a)], summarizing current knowledge about its causal association with atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. One of the novelties of this statement is a new risk calculator showing how Lp(a) influences lifetime risk for ASCVD and that global risk may be underestimated substantially in individuals with high or very high Lp(a) concentration. The statement also provides practical advice on how knowledge about Lp(a) concentration can be used to modulate risk factor management, given that specific and highly effective mRNA-targeted Lp(a)-lowering therapies are still in clinical development. This advice counters the attitude: Why should I measure Lp(a) if I can't lower it?. Subsequent to publication, questions have arisen relating to how the recommendations of this statement impact everyday clinical practice and ASCVD management. This review addresses 30 of the most frequently asked questions about Lp(a) epidemiology, its contribution to car-diovascular risk, Lp(a) measurement, risk factor management and existing therapeutic options.

Automated summary

In 2022, the European Atherosclerosis Society (EAS) released a new consensus statement on the relationship between lipoprotein(a) [Lp(a)] and atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. This statement highlights the importance of understanding Lp(a) concentration and its impact on lifetime risk for ASCVD. It also provides practical advice on using Lp(a) concentration to manage risk factors, despite the lack of currently available targeted therapies to lower Lp(a).